The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor-Associated Genitourinary Infections.

Anthony GerberVictoria RuppNatalia RyabenkovaNataliya Mikhelzon

Published in: The Annals of pharmacotherapy (2024)

Type 2 diabetes patients initiated on SGLT2is may experience an increased risk of GU infection, especially in those patients with an A1C of 9% or greater. Further research is necessary to validate and expand upon these findings.

Keyphrases

glycemic control
type diabetes
end stage renal disease
blood glucose
newly diagnosed
ejection fraction
prognostic factors
cardiovascular disease
weight loss
patient reported outcomes
skeletal muscle